#monoclonal antibody

Immunological Applications

Denosumab targets which pathway?

Skeletal remodeling balance controlled by triad RANKL-RANK-osteoprotegerin discovered late 1990s as final common pathway for osteoclastogenesis. RANKL encoded by TNFSF11 gene chromosome 13q14 expressed as type II membrane protein and cleaved soluble form by metalloproteinases TACE from osteoblasts, osteocytes responding to parathyroid hormone, active vitamin D3, and inflammatory cytokines interleukin-1, tumor necrosis factor, and activated T cells expressing RANKL contributing to inflammatory bone loss. Binding to RANK receptor TNFRSF11A on monocyte-macrophage precursors belonging to tumor necrosis factor receptor family activates adaptor protein TRAF6 that recruits TAK1 activating NF-kB p50/p65, c-Fos, and calcium signaling via PLCγ leading to induction of master transcription factor NFATc1 autoamplification driving fusion into multinucleated 10-20 nuclei osteoclasts expressing tartrate-resistant acid phosphatase, cathepsin K cysteine protease degrading collagen type I telopeptides, and vacuolar proton pump ATPase acidifying resorption pit to pH 4.5 dissolving hydroxyapatite. Denosumab fully human IgG2-kappa antibody selected via transgenic XenoMouse displaying picomolar affinity for RANKL, mimicking endogenous decoy osteoprotegerin TNFRSF11B.

Ref: Boyle et al Nature 2003 423:337 RANKL RANK OPG axis; Denosumab FDA label TNFSF11 neutralization osteoporosis.

View Details

Immunological Applications

Omalizumab is used in treatment of:

Severe persistent allergic asthma pathophysiology centers on Th2 polarization with interleukin-4 and interleukin-13 driving class switch recombination from IgM to IgE mediated by AID and germline ε transcription in B cells within bronchial associated lymphoid tissue. Secreted IgE circulates at low concentration 150 ng per ml but binds extremely high affinity FcεRI alpha chain Kd 10^-10 M on mast cells and basophils through Cε3 domain interaction, sensitizing them for months despite short serum half-life two days. Upon re-exposure to perennial aeroallergen such as Dermatophagoides pteronyssinus Der p1, multivalent allergen crosslinks receptor-bound IgE triggering Lyn and SYK tyrosine kinase activation, phospholipase Cγ mediated calcium rise, degranulation releasing preformed histamine causing bronchial smooth muscle contraction, mucus hypersecretion, vascular permeability, plus newly synthesized leukotriene C4, prostaglandin D2, and cytokines IL-5 recruiting eosinophils. Omalizumab humanized IgG1 binds Cε3 domain of free IgE at site overlapping FcεRI binding interface forming small biologically inert trimers cleared by hepatic reticuloendothelial Kupffer cells.

Ref: GINA 2023 severe asthma Omalizumab IgE; Holgate Nat Rev Immunol anti-IgE Cε3 blocks FcεRI downregulation.

View Details

Immunological Applications

Rituximab targets which antigen?

MS4A1 gene on chromosome 11q12.2 encodes CD20 differentiation antigen, 33 to 37 kDa tetra-spanning membrane phosphoprotein with both N and C termini intracellular, four transmembrane helices forming tetrameric oligomer functioning as store-operated calcium channel component modulating B cell receptor induced calcium flux via interaction with calcium release-activated calcium modulator ORAI1. Expression tightly regulated during ontogeny: absent on hematopoietic stem cells and early pro-B, appears at late pro-B stage after productive immunoglobulin heavy chain rearrangement, persists through mature naive, germinal center, memory B cells, but extinguished upon plasma cell differentiation when transcription factors BLIMP1 and XBP1 repress MS4A1 and induce secretory program. Lack on stem cells ensures regenerative capacity after depletion; absence on long-lived plasma cells preserves humoral memory maintaining protective antibody titers against prior vaccines. Rituximab binding extracellular loops between transmembrane domains 3-4 induces translocation to lipid rafts enriched in cholesterol and sphingolipid, enhancing Lyn mediated PLCγ2 activation, calcium mobilization, and Bax mediated mitochondrial apoptosis. Concurrent opsonization promotes phagocytosis by macrophages via FcγRI and complement. Reconstitution from pro-B precursors occurs within six to twelve months, infection risk transient compared to continuous pan-B ablation.

Ref: NCBI Gene MS4A1 CD20 tetra-span; Janeway Immunobiology CD20 calcium channel rituximab ADCC CDC.

View Details

Immunological Applications

Trastuzumab (Herceptin) is used in treatment of:

Alemtuzumab humanized IgG1 mAb 150 kDa directed CD52 glycopeptide 21-28 kDa GPI-anchored highly expressed 500k copies normal malignant B T lymphocytes monocytes macrophages eosinophils dendritic cells but absent HSC permitting immune reconstitution after depletion absent neutrophils limiting neutropenia. CD52 function incompletely understood proposed T-costimulation binding Siglec-10 inhibitory modulating migration L-selectin. Binding clusters GPI protein lipid rafts inducing proximity Fc enabling C1q multivalent binding activating classical complement C4 C2 cleavage forming C3 convertase C4b2a opsonizing C3b membrane attack complex C5b-9 osmotic lysis. Simultaneously Fc gamma RI CD64 macrophages Fc gamma RIIIa CD16a NK engage triggering ADCC perforin granzyme B caspase-3 phagocytosis clearing circulating lymphocytes within hours profound lymphopenia year. Repopulation B cells returning 6 months CD8 12 months CD4 longer regulatory T dominance inducing tolerance. Indications B-CLL previously and relapsing multiple sclerosis as induction immune reset therapy requiring monitoring thyroid autoimmunity due reconstitution aberration and anti-GBM disease risk managed REMS program.

Ref: Hale 1983 Transplantation Alemtuzumab CD52 Expression; FDA Campath Lemtrada Label CD52 Depletion; Janeway CD52 Depletion Reconstitution Chapter 14.

View Details

Basic Applied Biology

Rituximab targets antigen:

Rituximab represents first chimeric anti-cancer monoclonal antibody approved 1997 targeting CD20, a 33 to 37 kDa non-glycosylated tetra-span membrane phosphoprotein encoded by MS4A1 gene on chromosome 11q12 expressed on pre-B through mature B lymphocytes but absent on hematopoietic stem cells, pro-B cells and terminally differentiated plasma cells. Protein architecture comprises four transmembrane domains with short intracellular termini and two extracellular loops accessible for antibody binding. Physiologic function involves regulation of calcium flux through modulating B cell receptor signaling threshold, affecting activation and differentiation. Rituximab binding via Fab region to CD20 extracellular loop triggers multiple effector mechanisms: complement-dependent cytotoxicity via C1q recruitment and membrane attack complex formation, antibody-dependent cellular cytotoxicity mediated by Fc region engaging Fc-gamma-RIIIa on natural killer cells releasing perforin, direct apoptosis induction via cross-linking, lipid raft clustering and activation of caspase 3, and phagocytosis by macrophages. Specific lineage restriction allows B cell depletion in non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis with subsequent regeneration from stem cells lacking CD20. Absence on other lineages minimizes off-target toxicity compared to CD4, CD8 or HER2 targets.

Ref: Maloney et al. Blood 1997 Rituximab ideal target; Reff et al. CD20 biology; PubMed review CD20 therapeutic target.

View Details

Cell Signaling ELR Pathways - I

Trastuzumab (Herceptin) targets

HER2, is consistent with established principles of cell signaling, receptor pharmacology and cellular regulation. Experimental measurements of binding parameters, genetic loss-of-function studies and pharmacological interventions all converge on the same interpretation. Related options address neighboring concepts but do not satisfy the precise criterion stated in the question.

Ref: NCERT Biology Class 11–12 Alberts et al Molecular Biology of the Cell Lodish et al, Molecular Cell Biology Cooper & Hausman, The Cell Abbas et al., Cellular and Molecular Immunology (for immunology sections)

View Details